Ahmed Mohanad, Yassin Mohamed A
Internal Medicine, Hamad Medical Corporation, Doha, QAT.
Hematology and Oncology, Hamad General Hospital, Doha, QAT.
Cureus. 2020 Jun 19;12(6):e8705. doi: 10.7759/cureus.8705.
Idiopathic thrombocytopenic purpura (ITP) is a disease in which the immune system attacks platelets and causes a decrease in their number, exposing the patient to bleeding risk. It is a diagnosis by exclusion. ITP usually presents as acute disease and is self-limiting in pediatric patients, while it tends to be chronic in adults. Eltrombopag is a thrombopoietin receptor agonist used as a second-line treatment for ITP. This drug is approved for use in adults as second-line therapy, but little is known about its use in the pediatric patient population. We report the case of a 14-year-old girl with chronic steroid-dependent ITP who responded well to eltrombopag and maintained treatment-free remission after stopping the drug.
特发性血小板减少性紫癜（ITP）是一种免疫系统攻击血小板并导致其数量减少，使患者面临出血风险的疾病。它是一种排除性诊断。ITP通常表现为急性疾病，在儿科患者中具有自限性，而在成人中往往呈慢性。艾曲泊帕是一种血小板生成素受体激动剂，用作ITP的二线治疗药物。该药物被批准用于成人的二线治疗，但对于其在儿科患者群体中的使用知之甚少。我们报告了一例14岁慢性类固醇依赖型ITP女孩的病例，她对艾曲泊帕反应良好，停药后维持了无治疗缓解状态。
